Yes I am a moron - I sold all my shares at $13.50 after seeing the abstract on Wednesday. Wish I would have held, stupid me!! What a moron, what am I going to do with all my gains. I guess I will just have to buy back tomorrow at around $6 or $7 and hope I can lose more to offset my gains.
Check out Edny Inui - she is a moron too I suppose, you have much more insight than someone holding a PHD in neuroscience who actually attended the conference.
The general consensus by CTAD attendees was that AVXL results were not ground breaking, revolutionary, or earth shattering - but something to watch as a potential treatment.
The trial itself is still way too early, and way too small to make any concrete judgement on efficacy. Also, the datapoints selected by AVXL are not yet proven to be correlated with treating AD.
There were several tweets by attendees on the CTAD "best of show" presentations, none of them mentioned AVXL in that list.
To sum up - AVXL should definitely proceed, but needs to conduct a real trial, including much larger population and more subjective and widely-accepted endpoints.
Definitely not a walk-off home run to win the World series, more like a walk in third inning.
FYI - just look at the tweets for #CTAD2015 or #CTAD and you will see the commentary.
Doesn't appear to be the blockbuster that everybody had hoped for - seems like a confirmation of the same results from the July update:
Results: The primary outcome of the study is safety, and ANAVEX 2-73 was well tolerated. In the secondary outcome endpoints preliminary analysis of data from subjects shows an average improvement of the MMSE score at week 5. A majority of all patients tested so far improved their respective MMSE score. The average EEG/ERP (P300 amplitude) signal also improved and also the average Cogstate test improved across the test batteries. Conclusions: Data collected so far indicate that ANAVEX 2-73 is safe and well tolerated. Interim results also show improved cognitive performance after drug administration in subjects with mild-to-moderate AD. The current results seem to justify a prospective comparison with current standard of care in a larger clinical trial study. A more complete set of results will be available at the time of the conference.
Duh, yes of course they knew the data when preparing the abstract you idiot. How can you put together a presentation on the data if you don't know what it is. They did not violate Reg FD.
Original title of the LATE BREAKING abstract, that was accepted by CTAD after submission deadline. Forget all the noise the shorts are saying - AVXL forced their way onto the national stage on Nov. 7. There is no way that anybody would put themselves into this position to deliver anything but absolutely fantastic results!!!
Next Monday will be XMAS for us longs!!
How's that working out for you, Sonya Colberg. Oh, and your 60 cent price target, that's a really great call, you will be up for analyst of the year I'm sure.
The question on the validity of this company has been answered
Scam companies don't get grants from major foundations (Michael J Fox Foundation).
Scam companies don't get priority presentations at global conferences.
Scam companies don't get $50m funding from major venture capital firms (Lincoln Park)
Scam companies don't get to ring NASDAQ bells.
Who are you going to trust? Street Sweeper versus the above four organizations?
Anavex is for real, this is going to be a mind blowing and meteoric rise!!!
Sentiment: Strong Buy
Bought the first day of the news back in July at .60 - .65. Been adding ever since, most of it between .80 and .130, but even added some last week at 1.85.
This is gonna be big folks!!
Did you catch this snippet from yesterday's release? I believe this is the first time I heard this language - ie, "reverse" (aka CURE)!!
"Preclinical data indicates that ANAVEX 2-73 has the potential to prevent, halt and/or reverse the course of Alzheimer’s disease."
It would have required approximately a 300% - 400% rise without the R/S, which even in the biotech market would not have been guaranteed, especially in the short term. The uplisting to Nasdaq has been in the works for some time now, and these decisions were made several weeks ago when the price was lingering in the low $1 range.
Read between the lines - the PR quote from CEO of "future success" would not have been made if the results were not extremely positive.
1/4 was very conservative RS in terms of Nasdaq minimum price requirement. Obviously that was driven in confidence that upcoming data will more than support that price!!!!
Sentiment: Strong Buy